AMGN
AMGEN Inc.

14,617
Mkt Cap
$157.07B
Volume
1.38M
52W High
$335.88
52W Low
$253.30
PE Ratio
23.87
AMGN Fundamentals
Price
$291.88
Prev Close
$292.89
Open
$292.89
50D MA
$288.10
Beta
0.48
Avg. Volume
2.68M
EPS (Annual)
$7.56
P/B
21.14
Rev/Employee
$1.19M
Loading...
Loading...
News
all
press releases
The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market
Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
Amgen (AMGN) closed at $292.89 in the latest trading session, marking a -1.04% move from the prior day.
Zacks·3d ago
News Placeholder
Top Research Reports for Amazon.com, Wells Fargo & Amgen
Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.
Zacks·3d ago
News Placeholder
Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amgen Inc. (NASDAQ: AMGN) breached their fiduciary duties to shareholders. If you currently...
Business Wire·4d ago
News Placeholder
Why Amgen (AMGN) Dipped More Than Broader Market Today
The latest trading day saw Amgen (AMGN) settling at $295.98, representing a -1.71% change from its previous close.
Zacks·4d ago
News Placeholder
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Zacks·6d ago
News Placeholder
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·7d ago
News Placeholder
FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PR Newswire THOUSAND OAKS, Calif., Oct. 17, 2025 Approval...
PR Newswire·9d ago
News Placeholder
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
Zacks·10d ago
News Placeholder
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Zacks·11d ago

Latest AMGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.